Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed acute myeloid leukemia (AML) according to the WHO classification system~  * High-risk disease~ * Newly diagnosed disease~ * Patients with secondary AML due to prior chemotherapy for a different malignancy are eligible~* No known inv(16), t(8;21), or t(15;17) cytogenetic abnormality~* No acute promyelocytic leukemia~* No CNS leukemia~PATIENT CHARACTERISTICS:~Age~* 18 to 59~Performance status~* ECOG 0-2~Life expectancy~* More than 6 months~Hematopoietic~* Not specified~Hepatic~* AST and ALT ≤ 2.5 times upper limit of normal~* Bilirubin normal~Renal~* Creatinine normal OR~* Creatinine clearance ≥ 60 mL/min~Cardiovascular~* Ejection fraction \> 50% by echocardiogram or MUGA~* No symptomatic congestive heart failure~* No unstable angina pectoris~* No cardiac arrhythmia~Immunologic~* No known HIV positivity~* No history of allergic reactions attributed to compounds of similar chemical or biological composition to tipifarnib~* No allergy to imidazoles (e.g., clotrimazole, ketoconazole, miconazole, or econazole)~* No ongoing or active infection~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other uncontrolled illness~* No psychiatric illness or social situation that would preclude study compliance~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No concurrent epoetin alfa~Chemotherapy~* See Disease Characteristics~* No prior chemotherapy for AML or myelodysplastic syndromes except hydroxyurea~Endocrine therapy~* Not specified~Radiotherapy~* No concurrent palliative radiotherapy~Surgery~* Not specified~Other~* More than 30 days since prior investigational agents~* No other concurrent investigational or commercial agents or therapies for the malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).